OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma (Nasdaq: OKYO) reported that Chief Development Officer and Director Gary S. Jacob, PhD, purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holding to 112,420 ordinary shares.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) reported that Chief Development Officer and Director Gary S. Jacob, PhD, purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holding to 112,420 ordinary shares.

The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Argus Jul 22 session 6 alerts

+5.56% close to close 1.3x rel. volume Open Argus

Details

News Market Reaction – OKYO

+4.3% Peak in 25 min

$71.90M Mkt Cap at Peak Alert

On Jul 22, the day this news came out, OKYO closed 5.56% above the previous close. Argus tracked a peak move of +4.3% during that session. Our momentum scanner recorded 6 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 22 session.

Key Figures

Shares purchased: 3,500 ordinary shares Purchase price: $1.40 per share Total holding: 112,420 ordinary shares +2 more

Shares purchased

3,500 ordinary shares

Chief Development Officer and Director purchase

Purchase price

$1.40 per share

NASDAQ transaction

Total holding

112,420 ordinary shares

Holding after purchase

Trial phase

Phase 3

Global pivotal clinical trial

Planned enrollment

approximately 111 patients

Global Phase 3 trial for neuropathic corneal pain

Historical Context

5 past events · Latest: Jul 21

5 events

1. Jul 21

   Conference presentation

   24h Move

   +5.1%

   Scheduled presentation at the H.C. Wainwright ophthalmology virtual conference

2. Jul 21

   Insider share purchase

   24h Move

   +5.1%

   Chairman purchased 25,000 ordinary shares at $1.40 per share

3. Jul 20

   Annual report filing

   24h Move

   -4.2%

   Annual report highlighted cash resources and accelerated Phase 3 development plans

4. Jul 08

   FDA trial feedback

   24h Move

   -5.1%

   FDA Type D feedback supported advancing urcosimod into a global Phase 3 trial

5. Jul 07

   Conference participation

   24h Move

   +8.7%

   Company scheduled a fireside chat at the Piper Sandler ophthalmology symposium

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, single-dose regimen

2 terms

phase 3 medical

"initiate a global Phase 3 pivotal clinical trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

single-dose regimen medical

"evaluate a single-dose regimen of urcosimod"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO Pharma (NASDAQ: OKYO) announce on July 22, 2026?

OKYO Pharma announced that Chief Development Officer and Director Gary S. Jacob bought 3,500 ordinary shares at $1.40 each. According to OKYO Pharma, this transaction increased his total holding to 112,420 ordinary shares, reflecting his current personal equity position in the company.

How many OKYO Pharma shares does Gary S. Jacob now hold after his July 2026 purchase?

After the latest transaction, Gary S. Jacob holds 112,420 ordinary shares of OKYO Pharma. According to OKYO Pharma, this follows his purchase of 3,500 additional shares on Nasdaq at $1.40 per share, as disclosed in the July 22, 2026 announcement.

At what price were the newly purchased OKYO Pharma (OKYO) shares acquired by Gary S. Jacob?

The newly purchased OKYO Pharma shares were acquired at $1.40 per share on Nasdaq. According to OKYO Pharma, Gary S. Jacob bought 3,500 ordinary shares at this price, which brought his total holding to 112,420 ordinary shares following the July 22, 2026 transaction.

What Phase 3 clinical trial is OKYO Pharma planning for neuropathic corneal pain (NCP)?

OKYO Pharma plans a global Phase 3 pivotal trial evaluating a single-dose regimen of urcosimod for NCP. According to OKYO Pharma, the trial is expected to start in the second half of this year and enroll approximately 111 patients with neuropathic corneal pain.

What does OKYO Pharma focus on in its clinical-stage pipeline for OKYO stock investors?

OKYO Pharma focuses on investigational therapies for neuropathic corneal pain and anterior segment eye diseases. According to OKYO Pharma, its lead efforts include planning a global Phase 3 pivotal trial of urcosimod in NCP, targeting around 111 patients under a single-dose treatment regimen.